Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharma developing investigational therapy Haduvio (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and RCC, announced its June–July 2026 event schedule.
Senior leaders will attend BIO International, Leerink Partners Therapeutics Forum, and ERS Cough Conference.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – TRVI
+6.30%
28 alerts
+6.30%Session close to close
+4.5%Peak in 3 hr 24 min
$2.38BMarket Cap
1.3xRel. Volume
In the Jun 17 session, TRVI gained 6.30%, reflecting a notable positive market reaction.
Argus tracked a peak move of +4.5% during that session.
Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility.
The stock moved +6.3% in the session following this news. A strong positive reaction aligns with Tre...
Analysis
The stock moved +6.3% in the session following this news. A strong positive reaction aligns with Trevi’s broader trajectory of increased visibility and recent balance sheet strengthening. The company had already raised about $173 million in April and reported Q1 2026 cash of $171.8 million, plus ~$162 million in net offering proceeds. Participation in major scientific and investor meetings may have reinforced interest in the Haduvio chronic cough program. Investors should watch for future data readouts and financing decisions that have previously driven sharper moves.
Key Figures
BIO International Convention dates:June 22–25, 2026Leerink Forum dates:July 14–15, 2026ERS Cough Conference dates:July 15–17, 2026
3 metrics
BIO International Convention datesJune 22–25, 2026BIO International Convention, San Diego
Leerink Forum datesJuly 14–15, 2026Leerink Partners Therapeutics Forum 2026, Boston
ERS Cough Conference datesJuly 15–17, 2026ERS Cough Conference 2026, London
Closing of $173M underwritten offering at $13 per share under S-3 shelf.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news—including financings, data/meeting presentations, and event participation—has usually led to modest price moves, with the April offering drawing the sharpest negative reaction.
Recent Company History
Over the past few months, Trevi has focused on financing and visibility for Haduvio. An April underwritten offering raised about $173 million and was followed by Q1 2026 results showing a net loss of $13.2 million and cash of $171.8 million, plus an additional ~$162 million in net proceeds. The company has also highlighted upcoming and recent scientific and investor events, including ATS presentations and multiple May investor conferences. Today’s June–July event schedule continues this pattern of active outreach around its chronic cough programs.
Key Terms
idiopathic pulmonary fibrosis, ipf, interstitial lung disease, ild, +3 more
7 terms
idiopathic pulmonary fibrosismedical
"treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF)"
Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.
ipfmedical
"chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF"
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease where scar tissue builds up in the lungs for reasons doctors don't fully understand, making it harder to breathe over time. For investors, IPF matters because it represents a clear medical need and a regulated market for treatments, so progress in clinical trials, regulatory approvals, or new therapies can materially affect the value of companies working on drugs or devices for this condition—much like a new road that could open access to a previously hard-to-reach town.
interstitial lung diseasemedical
"non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough"
A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.
ildmedical
"non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough"
Interstitial lung disease (ILD) is a group of conditions that cause scarring and inflammation of the lung tissue responsible for moving oxygen into the bloodstream; think of it as the spongy part of the lungs becoming stiff and less able to stretch. For investors, ILD matters because it drives demand for diagnostic tests, treatments, and clinical trials, affects regulatory and safety profiles for drugs, and can influence the commercial outlook and risk profile of companies in respiratory and biotech sectors.
refractory chronic coughmedical
"non-IPF ILD), and refractory chronic cough (RCC), today announced"
A refractory chronic cough is a long-lasting cough that persists despite standard medical evaluation and treatment, typically lasting eight weeks or more and not improving with usual therapies. Investors should care because it represents a clear unmet medical need that can drive demand for new drugs, devices, or diagnostics—similar to a stubborn problem customers keep returning to a store for until a better solution appears—affecting market potential and regulatory attention.
rccmedical
"non-IPF ILD), and refractory chronic cough (RCC), today announced"
Renal cell carcinoma (RCC) is the most common type of kidney cancer, arising when cells in the kidney grow out of control and form a tumor. Investors watch RCC closely because success or failure of new tests and treatments, clinical trial results, and regulatory decisions can quickly change a drug maker’s revenue prospects and stock value — think of it like betting on whether a new repair will fix a widespread problem in cars and capture the replacement market.
nalbuphine ermedical
"investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment"
Nalbuphine ER is a long-acting formulation of nalbuphine, a pain medicine that activates some opioid receptors while blocking others to reduce pain and lower the risk of typical opioid side effects and misuse. For investors, an extended-release version matters because it can offer more predictable, sustained sales and prescribing patterns compared with short-acting drugs, shape regulatory review and safety perceptions, and compete differently in the pain-treatment market — like a slow-release pill versus a quick-relief aspirin.
NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will attend several upcoming events in June and July.
BIO International Convention June 22-25, 2026, San Diego, California Trevi Representatives:Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO
Leerink Partners Therapeutics Forum 2026 July 14-15, 2026, Boston, Massachusetts Trevi Representatives: David Hastings, CFO, and Farrell Simon, Pharm.D., CCO
ERS Cough Conference 2026 July 15-17, 2026, London, United Kingdom Trevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDO
About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF-related chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.
Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.
RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
What events will Trevi Therapeutics (TRVI) attend in June and July 2026?
Trevi Therapeutics will attend the BIO International Convention, Leerink Partners Therapeutics Forum 2026, and ERS Cough Conference 2026. According to Trevi, these meetings feature its senior leadership engaging with industry, investors, and scientific audiences across the United States and the United Kingdom.
When and where is Trevi Therapeutics presenting at BIO International Convention 2026?
Trevi Therapeutics will attend the BIO International Convention from June 22–25, 2026, in San Diego, California. According to Trevi, President and CEO Jennifer Good and Chief Commercial Officer Farrell Simon will represent the company at this major biopharmaceutical industry gathering.
Which Trevi Therapeutics executives will attend Leerink Partners Therapeutics Forum 2026?
Trevi’s Chief Financial Officer David Hastings and Chief Commercial Officer Farrell Simon will attend Leerink Partners Therapeutics Forum 2026. According to Trevi, the forum takes place July 14–15, 2026, in Boston, Massachusetts, offering meetings with healthcare-focused investors and industry participants.
What is Trevi Therapeutics’ involvement in the ERS Cough Conference 2026?
Trevi Therapeutics will participate in the ERS Cough Conference 2026 from July 15–17, 2026, in London, United Kingdom. According to Trevi, President and CEO Jennifer Good and Chief Development Officer James Cassella will represent the company at this cough-focused scientific meeting.
What therapy is Trevi Therapeutics (TRVI) developing and for which indications?
Trevi Therapeutics is developing investigational therapy Haduvio, an oral extended-release nalbuphine. According to Trevi, Haduvio targets chronic cough in idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC) as part of its clinical-stage program.
Who are the key Trevi Therapeutics executives highlighted in the June–July 2026 events?
Key Trevi Therapeutics executives include President and CEO Jennifer Good, CFO David Hastings, CCO Farrell Simon, and CDO James Cassella. According to Trevi, these leaders will represent the company across BIO International, Leerink Partners Therapeutics Forum, and the ERS Cough Conference.
